GLPwatch
Papers (10389)
Page 168 of 174, ranked by citation count.
- Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.
- Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis.
- GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model.
- Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.
- Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.
- The role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.
- Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?
- [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
- [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
- Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.
- Management of the T2D Patient With High A1C.
- Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.
- Developing <sup>68</sup>Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.
- Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
- Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study.
- Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
- Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
- Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.
- Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
- Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways.
- GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
- Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
- THE AUTHORS RESPOND.
- Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.
- Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.
- Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service.
- Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation.
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
- The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.
- The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
- Gila Monster Lizard & Incretin-mimetics.
- Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model.
- Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.
- Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
- Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.
- Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
- A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa.
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.
- Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
- Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.
- Swiss obesity clinical practice guidance.
- Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America.
- Retatrutide in type 2 diabetes mellitus and obesity: an overview.
- Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.
- Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.
- Patient Experiences With GLP-1 Receptor Agonists.
- Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.
- [Liraglutide in polycystic ovary syndrome].
- Challenges in the management of obesity.
- Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.